Rallybio wades into Sanofi storeroom for $3M rare disease deal
Rallybio wades into Sanofi storeroom for $3M rare disease deal [...]
Cortexyme shakes things up with Novosteo acquisition, leadership change and a new name
Cortexyme shakes things up with Novosteo acquisition, leadership change and [...]
Starting gun? $11.6B M&A domino falls as Pfizer scoops up Biohaven for phase 3 migraine nasal spray
Starting gun? $11.6B M&A domino falls as Pfizer scoops up [...]
Eisai wraps filing for Biogen-partnered Aduhelm followup, hoping to regain ‘credibility and trust’
Eisai wraps filing for Biogen-partnered Aduhelm followup, hoping to regain [...]
Sesen Bio reports progress with regulators as it preps for new cancer trial, but issues remain
Sesen Bio reports progress with regulators as it preps for [...]
Investors take root in Aspen Neuroscience’s customized cell therapy as $147.5M round closes
Investors take root in Aspen Neuroscience’s customized cell therapy as [...]
UPDATE: VistaGen says regulators couldn’t sniff out abuse potential of its nasal spray for social anxiety
UPDATE: VistaGen says regulators couldn’t sniff out abuse potential of [...]
With Sarepta in its sights, PepGen prices IPO to fund DMD trials
With Sarepta in its sights, PepGen prices IPO to fund [...]
Bye-bye: Xencor culls 2 bispecifics after early-phase solid tumor data underwhelm
Bye-bye: Xencor culls 2 bispecifics after early-phase solid tumor data [...]
Orion aims to challenge Vertex with new pain management licensing deal
Orion aims to challenge Vertex with new pain management licensing [...]